Policy Brief
A Call to Action for Diversity in Clinical Trials
JM
SHARE
JM
SHARE
Resource Downloads
Full Report
FasterCures has initiated a body of work to advance system change within biomedical research to focus on and value diversity and representation within clinical trials. Following our report, 'Achieving Health Equity: A Multi-Stakeholder Action Plan to Address Diversity across the Clinical Trials Enterprise and the Biomedical Research Ecosystem', released in November 2021, this policy brief highlights current and proposed policies with recommendations to reform an unequal research ecosystem. Throughout 2021, FasterCures delivered formal comments and recommendations for several pieces of draft legislation included in this brief. Other policies on the horizon are included to complete the picture of current legislative policies proposed to address diversity in clinical trials.
Resource Downloads
Full Report
Image
Athena Rae Roesler
Director, Public Health, Milken Institute Health
Athena Rae Roesler is a director on the Public Health team at Milken Institute Health, where she leads a portfolio of work focused on prevention and chronic disease.
SHARE
Related Content
-
Patients Most In Need Face Obstacles to Participating in Life-Saving Clinical Trials According to a New Milken Institute Report
June 24, 2024 (Washington, DC)— Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving treatments are often difficult or impossible...Read ArticleImage
Paul Guequierre
Director, Strategic CommunicationsPaul Guequierre is the director of strategic communications. In this role, he works to increase the profile of Milken Institute in the media, raise the visibility of issues important to the organization and its stakeholders, and expand the Institute's digital presence. -
Key Trends in Health at the Future of Health Summit 2023
In the United States and globally, we are in the golden age of rapid advances in scientific innovation and technology for a wide variety of health challenges. However, health outcomes continue to decline across populations in the US, as...Read Report -
Demographic Reporting and Mix in Clinical Trials
Clinical trial enrollment can vary based on demographics. Cancer drug trials, for example, have been shown to skew disproportionately toward young, White, male participants. Variability also exists in a treatment’s effectiveness across...Read Report
-
Key Trends in Health at Milken Institute Global Conference 2023
The 26th annual Milken Institute Global Conference convened the best minds in the world to tackle its most urgent challenges and realize its most exciting opportunities. Throughout the four-day event, our health teams curated nearly three...Read Report -
Mapping the Journey: Building a Mutual Understanding for Health Equity in Clinical Research
If the objective of biomedical research is to spur innovation to create healthier communities, extend life, and more effectively treat or cure disease, then persistent inequities run counter to that goal and create unnecessary barriers to...Read Report
KO
-
Increasing Diversity in Clinical Trials to Reduce Health Disparities
In an incredibly diverse world, health inequities and resulting disparities continue to stand out as a persistent yet addressable challenge. As the global biopharmaceutical industry works to treat, prevent, or even cure diseases, we have a...Read Essay -
A Call to Action for Health Equity: Solutions from the Front Lines for Local and National Efforts
FasterCures is advancing system change within biomedical research to focus on and value diversity and representation within clinical trials and the workforce. In addition to our “ Achieving Health Equity” report, we released a Policy Issue...Read Report
-
Achieving Health Equity: A Multi-Stakeholder Action Plan to Address Diversity across the Clinical Trials Enterprise and the Biomedical Research Ecosystem
Clinical trials have been used for decades as the primary way by which researchers determine if a new treatment is safe and effective for human use. Within the biomedical research ecosystem, participants in clinical trials often do not...Read Report
